Understanding Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) with Dr. Ricardo Rendon

Understanding Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) with Dr. Ricardo Rendon

Today, we are speaking with Dr. Ricardo Rendon from Dalhousie University on the topic of prostate cancer, and more specifically, non-metastatic castrate resistant prostate cancer.

Prostate Cancer is the third leading cause of male cancer mortality in Canada. However, survival has been improving over the years. During a prostate cancer journey, a patient is first tested to determine if the disease is contained to the prostate or is growing outside of it as well. Treatments for localized prostate cancer usually include surgery, or removal of the prostate gland, but there can also be radiation required. If that is not working, doctors may also begin hormone therapy. Dr. Rendon will other discuss other tools that can be utilized as well.

We’ll also hear from Barry and Helen Ghent. Barry was diagnosed with non-metastatic castrate resistant prostate cancer in November of 2015. Thanks to his involvement with Dr. Rendon, they are living full lives, rising early every day to tend to their animals and extensive gardens. Life hasn’t changed much since Barry’s diagnosis.

Dr. Ricardo Rendon
Urologist Oncologist, Halifax, Nova Scotia Professor Department Urology, Dalhousie University

Vice-President of Education of the Canadian Urological Association, Canadian Urologic Oncology Group

Barry Gent age 70
Diagnosed nmCRPC (non-metastatic castrate-resistant prostate cancer)

For more information on nmCRPC, please speak with your healthcare professional or visit www.procure.ca

This educational program was made possible by: